{"id":915902,"date":"2025-12-03T16:04:34","date_gmt":"2025-12-03T21:04:34","guid":{"rendered":"https:\/\/www.marketnewsdesk.com\/index.php\/oric-pharmaceuticals-announces-enozertinib-oric-114-late-breaking-oral-presentations-in-egfr-atypical-and-egfr-exon-20-nsclc-at-the-esmo-asia-congress-2025\/"},"modified":"2025-12-03T16:04:34","modified_gmt":"2025-12-03T21:04:34","slug":"oric-pharmaceuticals-announces-enozertinib-oric-114-late-breaking-oral-presentations-in-egfr-atypical-and-egfr-exon-20-nsclc-at-the-esmo-asia-congress-2025","status":"publish","type":"post","link":"https:\/\/www.marketnewsdesk.com\/index.php\/oric-pharmaceuticals-announces-enozertinib-oric-114-late-breaking-oral-presentations-in-egfr-atypical-and-egfr-exon-20-nsclc-at-the-esmo-asia-congress-2025\/","title":{"rendered":"ORIC\u00ae Pharmaceuticals Announces Enozertinib (ORIC-114) Late-Breaking Oral Presentations in EGFR Atypical and EGFR exon 20 NSCLC at the ESMO Asia Congress 2025"},"content":{"rendered":"

\nCompany to host a conference call and webcast on Saturday, December 6, 2025, at 8:00 pm ET
\n<\/h2>\n
\n

SOUTH SAN FRANCISCO and SAN DIEGO, Dec. 03, 2025 (GLOBE NEWSWIRE) — ORIC Pharmaceuticals, Inc. (Nasdaq: ORIC), a clinical stage oncology company focused on developing treatments that address mechanisms of therapeutic resistance, today announced two late-breaking oral presentations highlighting data from a Phase 1b trial of enozertinib (ORIC-114) at the ESMO Asia Congress 2025 taking place December 5-7, 2025 in Singapore. The mini-oral presentation will focus on data in previously treated patients with EGFR atypical mutant NSCLC, and the proffered paper oral presentation will focus on data in previously treated and treatment-na\u00efve patients with EGFR exon 20 mutant NCSLC.<\/p>\n\n\n\n\n\n\n\n
\n
\n Mini-oral presentation details:<\/u>
\n <\/strong>
\n \n <\/td>\n<\/tr>\n
\u00a0<\/td>\n\u00a0<\/td>\n<\/tr>\n
\n Title:<\/strong>\u00a0<\/td>\nEnozertinib (ORIC-114), a Highly Selective, Brain Penetrant
EGFR and HER2 Inhibitor, in Previously Treated NSCLC with
EGFR Atypical Mutations: Randomized Dose Optimization and
CNS Activity<\/td>\n<\/tr>\n
\n Presentation Number:<\/strong>\n <\/td>\nLBA15<\/td>\n<\/tr>\n
\n Session Type and Title:<\/strong>\n <\/td>\nMini Oral session 1: Thoracic malignancies<\/td>\n<\/tr>\n
\n Lecture Date and Time:<\/strong>\n <\/td>\nFriday, December 5, 2025; 11:38 \u2013 11:43 a.m. SGT<\/td>\n<\/tr>\n<\/table>\n

\n
\n
\n
\n <\/u>
\n <\/strong>\n <\/p>\n\n\n\n\n\n\n\n
\n
\n Proffered paper oral presentation details:<\/u>
\n <\/strong>
\n \n <\/td>\n<\/tr>\n
\u00a0<\/td>\n\u00a0<\/td>\n<\/tr>\n
\n Title:<\/strong>\u00a0<\/td>\nEnozertinib (ORIC-114), a Highly Selective, Brain Penetrant
EGFR and HER2 Inhibitor, in EGFR Exon 20 Mutant NSCLC:
Randomized Dose Optimization and CNS Activity<\/td>\n<\/tr>\n
\n Presentation Number:<\/strong>\n <\/td>\nLBA13<\/td>\n<\/tr>\n
\n Session Type and Title:<\/strong>\n <\/td>\nProffered Paper session: Thoracic malignancies<\/td>\n<\/tr>\n
\n Lecture Date and Time:<\/strong>\u00a0<\/td>\nSaturday, December 6, 2025; 10:02 \u2013 10:12 a.m. SGT<\/td>\n<\/tr>\n<\/table>\n

\n
Full late-breaking abstracts are available for public viewing via the ESMO Asia Congress website<\/u><\/a>.<\/p>\n

\n Conference Call and Webcast Details<\/strong>
\n
In conjunction with the ESMO Asia Congress, ORIC will host a conference call and webcast on Saturday, December 6, 2025, at 8:00 pm ET. To join the conference call via phone and participate in the live Q&A session, please pre-register online here<\/a> to receive a telephone number and unique passcode required to enter the call. A live webcast and audio archive of the conference call will be available through the investor section of ORIC\u2019s website at www.oricpharma.com<\/u><\/a>. The webcast will be available for replay for 90 days following the presentation.<\/p>\n

\n About ORIC Pharmaceuticals, Inc. <\/strong>
\n
ORIC Pharmaceuticals is a clinical stage biopharmaceutical company dedicated to improving patients\u2019 lives by Overcoming Resistance In Cancer<\/em>. ORIC\u2019s clinical stage product candidates include (1) ORIC-944, an allosteric inhibitor of the polycomb repressive complex 2 (PRC2) via the EED subunit, being developed for prostate cancer, and (2) enozertinib (ORIC-114), a brain-penetrant inhibitor that selectively targets EGFR exon 20, EGFR atypical, and HER2 exon 20 mutations, being developed across multiple genetically defined cancers. ORIC has offices in South San Francisco and San Diego, California. For more information, please go to\u00a0www.oricpharma.com<\/u><\/a>, and follow us on\u00a0X<\/u><\/a>\u00a0or LinkedIn<\/u><\/a>.<\/p>\n

\n Contact:<\/strong>\n <\/p>\n

Dominic Piscitelli, Chief Financial Officer
dominic.piscitelli@oricpharma.com<\/u><\/a>
info@oricpharma.com<\/u><\/a><\/p>\n

\"\"
\n
\n \"\"\n <\/div>\n

<\/div>\n","protected":false},"excerpt":{"rendered":"

Company to host a conference call and webcast on Saturday, December 6, 2025, at 8:00 pm ET SOUTH SAN FRANCISCO and SAN DIEGO, Dec. 03, 2025 (GLOBE NEWSWIRE) — ORIC Pharmaceuticals, Inc. (Nasdaq: ORIC), a clinical stage oncology company focused on developing treatments that address mechanisms of therapeutic resistance, today announced two late-breaking oral presentations highlighting data from a Phase 1b trial of enozertinib (ORIC-114) at the ESMO Asia Congress 2025 taking place December 5-7, 2025 in Singapore. The mini-oral presentation will focus on data in previously treated patients with EGFR atypical mutant NSCLC, and the proffered paper oral presentation will focus on data in previously treated and treatment-na\u00efve patients with EGFR exon 20 mutant NCSLC. Mini-oral presentation details: \u00a0 … <\/p>\n

Continue reading “ORIC\u00ae Pharmaceuticals Announces Enozertinib (ORIC-114) Late-Breaking Oral Presentations in EGFR Atypical and EGFR exon 20 NSCLC at the ESMO Asia Congress 2025”<\/span><\/a><\/p>\n","protected":false},"author":2,"featured_media":0,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[],"tags":[],"class_list":["post-915902","post","type-post","status-publish","format-standard","hentry"],"yoast_head":"\nORIC\u00ae Pharmaceuticals Announces Enozertinib (ORIC-114) Late-Breaking Oral Presentations in EGFR Atypical and EGFR exon 20 NSCLC at the ESMO Asia Congress 2025 - Market Newsdesk<\/title>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/www.marketnewsdesk.com\/index.php\/oric-pharmaceuticals-announces-enozertinib-oric-114-late-breaking-oral-presentations-in-egfr-atypical-and-egfr-exon-20-nsclc-at-the-esmo-asia-congress-2025\/\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"ORIC\u00ae Pharmaceuticals Announces Enozertinib (ORIC-114) Late-Breaking Oral Presentations in EGFR Atypical and EGFR exon 20 NSCLC at the ESMO Asia Congress 2025 - Market Newsdesk\" \/>\n<meta property=\"og:description\" content=\"Company to host a conference call and webcast on Saturday, December 6, 2025, at 8:00 pm ET SOUTH SAN FRANCISCO and SAN DIEGO, Dec. 03, 2025 (GLOBE NEWSWIRE) — ORIC Pharmaceuticals, Inc. (Nasdaq: ORIC), a clinical stage oncology company focused on developing treatments that address mechanisms of therapeutic resistance, today announced two late-breaking oral presentations highlighting data from a Phase 1b trial of enozertinib (ORIC-114) at the ESMO Asia Congress 2025 taking place December 5-7, 2025 in Singapore. The mini-oral presentation will focus on data in previously treated patients with EGFR atypical mutant NSCLC, and the proffered paper oral presentation will focus on data in previously treated and treatment-na\u00efve patients with EGFR exon 20 mutant NCSLC. Mini-oral presentation details: \u00a0 … Continue reading "ORIC\u00ae Pharmaceuticals Announces Enozertinib (ORIC-114) Late-Breaking Oral Presentations in EGFR Atypical and EGFR exon 20 NSCLC at the ESMO Asia Congress 2025"\" \/>\n<meta property=\"og:url\" content=\"https:\/\/www.marketnewsdesk.com\/index.php\/oric-pharmaceuticals-announces-enozertinib-oric-114-late-breaking-oral-presentations-in-egfr-atypical-and-egfr-exon-20-nsclc-at-the-esmo-asia-congress-2025\/\" \/>\n<meta property=\"og:site_name\" content=\"Market Newsdesk\" \/>\n<meta property=\"article:published_time\" content=\"2025-12-03T21:04:34+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=OTU5NTgzNyM3MzAzMjgxIzIwODA4ODU=\" \/>\n<meta name=\"author\" content=\"Newsdesk\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Newsdesk\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"2 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/oric-pharmaceuticals-announces-enozertinib-oric-114-late-breaking-oral-presentations-in-egfr-atypical-and-egfr-exon-20-nsclc-at-the-esmo-asia-congress-2025\\\/#article\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/oric-pharmaceuticals-announces-enozertinib-oric-114-late-breaking-oral-presentations-in-egfr-atypical-and-egfr-exon-20-nsclc-at-the-esmo-asia-congress-2025\\\/\"},\"author\":{\"name\":\"Newsdesk\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\"},\"headline\":\"ORIC\u00ae Pharmaceuticals Announces Enozertinib (ORIC-114) Late-Breaking Oral Presentations in EGFR Atypical and EGFR exon 20 NSCLC at the ESMO Asia Congress 2025\",\"datePublished\":\"2025-12-03T21:04:34+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/oric-pharmaceuticals-announces-enozertinib-oric-114-late-breaking-oral-presentations-in-egfr-atypical-and-egfr-exon-20-nsclc-at-the-esmo-asia-congress-2025\\\/\"},\"wordCount\":446,\"image\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/oric-pharmaceuticals-announces-enozertinib-oric-114-late-breaking-oral-presentations-in-egfr-atypical-and-egfr-exon-20-nsclc-at-the-esmo-asia-congress-2025\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=OTU5NTgzNyM3MzAzMjgxIzIwODA4ODU=\",\"inLanguage\":\"en-US\"},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/oric-pharmaceuticals-announces-enozertinib-oric-114-late-breaking-oral-presentations-in-egfr-atypical-and-egfr-exon-20-nsclc-at-the-esmo-asia-congress-2025\\\/\",\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/oric-pharmaceuticals-announces-enozertinib-oric-114-late-breaking-oral-presentations-in-egfr-atypical-and-egfr-exon-20-nsclc-at-the-esmo-asia-congress-2025\\\/\",\"name\":\"ORIC\u00ae Pharmaceuticals Announces Enozertinib (ORIC-114) Late-Breaking Oral Presentations in EGFR Atypical and EGFR exon 20 NSCLC at the ESMO Asia Congress 2025 - Market Newsdesk\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/oric-pharmaceuticals-announces-enozertinib-oric-114-late-breaking-oral-presentations-in-egfr-atypical-and-egfr-exon-20-nsclc-at-the-esmo-asia-congress-2025\\\/#primaryimage\"},\"image\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/oric-pharmaceuticals-announces-enozertinib-oric-114-late-breaking-oral-presentations-in-egfr-atypical-and-egfr-exon-20-nsclc-at-the-esmo-asia-congress-2025\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=OTU5NTgzNyM3MzAzMjgxIzIwODA4ODU=\",\"datePublished\":\"2025-12-03T21:04:34+00:00\",\"author\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\"},\"breadcrumb\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/oric-pharmaceuticals-announces-enozertinib-oric-114-late-breaking-oral-presentations-in-egfr-atypical-and-egfr-exon-20-nsclc-at-the-esmo-asia-congress-2025\\\/#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/oric-pharmaceuticals-announces-enozertinib-oric-114-late-breaking-oral-presentations-in-egfr-atypical-and-egfr-exon-20-nsclc-at-the-esmo-asia-congress-2025\\\/\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/oric-pharmaceuticals-announces-enozertinib-oric-114-late-breaking-oral-presentations-in-egfr-atypical-and-egfr-exon-20-nsclc-at-the-esmo-asia-congress-2025\\\/#primaryimage\",\"url\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=OTU5NTgzNyM3MzAzMjgxIzIwODA4ODU=\",\"contentUrl\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=OTU5NTgzNyM3MzAzMjgxIzIwODA4ODU=\"},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/oric-pharmaceuticals-announces-enozertinib-oric-114-late-breaking-oral-presentations-in-egfr-atypical-and-egfr-exon-20-nsclc-at-the-esmo-asia-congress-2025\\\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"ORIC\u00ae Pharmaceuticals Announces Enozertinib (ORIC-114) Late-Breaking Oral Presentations in EGFR Atypical and EGFR exon 20 NSCLC at the ESMO Asia Congress 2025\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#website\",\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/\",\"name\":\"Market Newsdesk\",\"description\":\"Latest Business News in Real Time\",\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Person\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\",\"name\":\"Newsdesk\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"url\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"contentUrl\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"caption\":\"Newsdesk\"},\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/author\\\/newsdesk\\\/\"}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"ORIC\u00ae Pharmaceuticals Announces Enozertinib (ORIC-114) Late-Breaking Oral Presentations in EGFR Atypical and EGFR exon 20 NSCLC at the ESMO Asia Congress 2025 - Market Newsdesk","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/www.marketnewsdesk.com\/index.php\/oric-pharmaceuticals-announces-enozertinib-oric-114-late-breaking-oral-presentations-in-egfr-atypical-and-egfr-exon-20-nsclc-at-the-esmo-asia-congress-2025\/","og_locale":"en_US","og_type":"article","og_title":"ORIC\u00ae Pharmaceuticals Announces Enozertinib (ORIC-114) Late-Breaking Oral Presentations in EGFR Atypical and EGFR exon 20 NSCLC at the ESMO Asia Congress 2025 - Market Newsdesk","og_description":"Company to host a conference call and webcast on Saturday, December 6, 2025, at 8:00 pm ET SOUTH SAN FRANCISCO and SAN DIEGO, Dec. 03, 2025 (GLOBE NEWSWIRE) — ORIC Pharmaceuticals, Inc. (Nasdaq: ORIC), a clinical stage oncology company focused on developing treatments that address mechanisms of therapeutic resistance, today announced two late-breaking oral presentations highlighting data from a Phase 1b trial of enozertinib (ORIC-114) at the ESMO Asia Congress 2025 taking place December 5-7, 2025 in Singapore. The mini-oral presentation will focus on data in previously treated patients with EGFR atypical mutant NSCLC, and the proffered paper oral presentation will focus on data in previously treated and treatment-na\u00efve patients with EGFR exon 20 mutant NCSLC. Mini-oral presentation details: \u00a0 … Continue reading \"ORIC\u00ae Pharmaceuticals Announces Enozertinib (ORIC-114) Late-Breaking Oral Presentations in EGFR Atypical and EGFR exon 20 NSCLC at the ESMO Asia Congress 2025\"","og_url":"https:\/\/www.marketnewsdesk.com\/index.php\/oric-pharmaceuticals-announces-enozertinib-oric-114-late-breaking-oral-presentations-in-egfr-atypical-and-egfr-exon-20-nsclc-at-the-esmo-asia-congress-2025\/","og_site_name":"Market Newsdesk","article_published_time":"2025-12-03T21:04:34+00:00","og_image":[{"url":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=OTU5NTgzNyM3MzAzMjgxIzIwODA4ODU=","type":"","width":"","height":""}],"author":"Newsdesk","twitter_card":"summary_large_image","twitter_misc":{"Written by":"Newsdesk","Est. reading time":"2 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/oric-pharmaceuticals-announces-enozertinib-oric-114-late-breaking-oral-presentations-in-egfr-atypical-and-egfr-exon-20-nsclc-at-the-esmo-asia-congress-2025\/#article","isPartOf":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/oric-pharmaceuticals-announces-enozertinib-oric-114-late-breaking-oral-presentations-in-egfr-atypical-and-egfr-exon-20-nsclc-at-the-esmo-asia-congress-2025\/"},"author":{"name":"Newsdesk","@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979"},"headline":"ORIC\u00ae Pharmaceuticals Announces Enozertinib (ORIC-114) Late-Breaking Oral Presentations in EGFR Atypical and EGFR exon 20 NSCLC at the ESMO Asia Congress 2025","datePublished":"2025-12-03T21:04:34+00:00","mainEntityOfPage":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/oric-pharmaceuticals-announces-enozertinib-oric-114-late-breaking-oral-presentations-in-egfr-atypical-and-egfr-exon-20-nsclc-at-the-esmo-asia-congress-2025\/"},"wordCount":446,"image":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/oric-pharmaceuticals-announces-enozertinib-oric-114-late-breaking-oral-presentations-in-egfr-atypical-and-egfr-exon-20-nsclc-at-the-esmo-asia-congress-2025\/#primaryimage"},"thumbnailUrl":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=OTU5NTgzNyM3MzAzMjgxIzIwODA4ODU=","inLanguage":"en-US"},{"@type":"WebPage","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/oric-pharmaceuticals-announces-enozertinib-oric-114-late-breaking-oral-presentations-in-egfr-atypical-and-egfr-exon-20-nsclc-at-the-esmo-asia-congress-2025\/","url":"https:\/\/www.marketnewsdesk.com\/index.php\/oric-pharmaceuticals-announces-enozertinib-oric-114-late-breaking-oral-presentations-in-egfr-atypical-and-egfr-exon-20-nsclc-at-the-esmo-asia-congress-2025\/","name":"ORIC\u00ae Pharmaceuticals Announces Enozertinib (ORIC-114) Late-Breaking Oral Presentations in EGFR Atypical and EGFR exon 20 NSCLC at the ESMO Asia Congress 2025 - Market Newsdesk","isPartOf":{"@id":"https:\/\/www.marketnewsdesk.com\/#website"},"primaryImageOfPage":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/oric-pharmaceuticals-announces-enozertinib-oric-114-late-breaking-oral-presentations-in-egfr-atypical-and-egfr-exon-20-nsclc-at-the-esmo-asia-congress-2025\/#primaryimage"},"image":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/oric-pharmaceuticals-announces-enozertinib-oric-114-late-breaking-oral-presentations-in-egfr-atypical-and-egfr-exon-20-nsclc-at-the-esmo-asia-congress-2025\/#primaryimage"},"thumbnailUrl":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=OTU5NTgzNyM3MzAzMjgxIzIwODA4ODU=","datePublished":"2025-12-03T21:04:34+00:00","author":{"@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979"},"breadcrumb":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/oric-pharmaceuticals-announces-enozertinib-oric-114-late-breaking-oral-presentations-in-egfr-atypical-and-egfr-exon-20-nsclc-at-the-esmo-asia-congress-2025\/#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/www.marketnewsdesk.com\/index.php\/oric-pharmaceuticals-announces-enozertinib-oric-114-late-breaking-oral-presentations-in-egfr-atypical-and-egfr-exon-20-nsclc-at-the-esmo-asia-congress-2025\/"]}]},{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/oric-pharmaceuticals-announces-enozertinib-oric-114-late-breaking-oral-presentations-in-egfr-atypical-and-egfr-exon-20-nsclc-at-the-esmo-asia-congress-2025\/#primaryimage","url":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=OTU5NTgzNyM3MzAzMjgxIzIwODA4ODU=","contentUrl":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=OTU5NTgzNyM3MzAzMjgxIzIwODA4ODU="},{"@type":"BreadcrumbList","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/oric-pharmaceuticals-announces-enozertinib-oric-114-late-breaking-oral-presentations-in-egfr-atypical-and-egfr-exon-20-nsclc-at-the-esmo-asia-congress-2025\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/www.marketnewsdesk.com\/"},{"@type":"ListItem","position":2,"name":"ORIC\u00ae Pharmaceuticals Announces Enozertinib (ORIC-114) Late-Breaking Oral Presentations in EGFR Atypical and EGFR exon 20 NSCLC at the ESMO Asia Congress 2025"}]},{"@type":"WebSite","@id":"https:\/\/www.marketnewsdesk.com\/#website","url":"https:\/\/www.marketnewsdesk.com\/","name":"Market Newsdesk","description":"Latest Business News in Real Time","potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/www.marketnewsdesk.com\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Person","@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979","name":"Newsdesk","image":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","url":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","caption":"Newsdesk"},"url":"https:\/\/www.marketnewsdesk.com\/index.php\/author\/newsdesk\/"}]}},"_links":{"self":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts\/915902","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/users\/2"}],"replies":[{"embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/comments?post=915902"}],"version-history":[{"count":0,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts\/915902\/revisions"}],"wp:attachment":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/media?parent=915902"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/categories?post=915902"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/tags?post=915902"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}